

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

中國神威藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO
THE POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 27 MAY 2022**

Reference is made to the announcement of China Shineway Pharmaceutical Group Limited (the “**Company**”) dated 27 May 2022 (the “**Announcement**”) in relation to, amongst others, the poll results of the annual general meeting (the “**AGM**”) held on 27 May 2022. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement.

This announcement is made pursuant to Rule 13.39(5A) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to provide supplemental information on the attendance of the directors of the Company (the “**Directors**”) at the AGM. All the Directors attended the AGM either in person or by electronic means.

Save as disclosed above, all information and contents set out in the Announcement remain unchanged.

By Order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 30 May 2022

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.